Human tumor-specific T lymphocytes: Does function matter more than number?

Current Opinion in Immunology

Volumn 17, Issue 3, 2005, Pages 320-325

  Coulie, Pierre G ^a   Connerotte, Thierry ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; FREUND ADJUVANT; GALECTIN 1; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN;

CANARYPOX VIRUS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL FUNCTION; CELLULAR IMMUNITY; CLINICAL TRIAL; CORRELATION ANALYSIS; CPG ISLAND; CYTOKINE PRODUCTION; HUMAN; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MELANOMA; MONITORING; NONHUMAN; OUTCOMES RESEARCH; REVIEW; T LYMPHOCYTE; TUMOR RESISTANCE; VACCINATION; VIRUS RECOMBINANT;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; NEOPLASMS;

EID: 18844447815     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2005.03.002     Document Type: Review

References (48)

1. S.A. Rosenberg, and M.E. Dudley Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes Proc Natl Acad Sci USA 101 2004 14639 14645 The clinical results reported here, in metastatic melanoma patients with bulky disease treated with conditioning chemotherapy, adoptive transfer of anti-tumor T cells, and IL-2, are the best to date with regard to cancer immunotherapy.
2. A. Rosato, A. Zoso, G. Milan, B. Macino, S. Dalla Santa, V. Tosello, E. Di Carlo, P. Musiani, R.G. Whalen, and P. Zanovello Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy J Immunol 171 2003 5172 5179
3. A. Perez-Diez, P.J. Spiess, N.P. Restifo, P. Matzinger, and F.M. Marincola Intensity of the vaccine-elicited immune response determines tumor clearance J Immunol 168 2002 338 347
4. C. Lonchay, P. van der Bruggen, T. Connerotte, T. Hanagiri, P. Coulie, D. Colau, S. Lucas, A. Van Pel, K. Thielemans, and N. van Baren Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen Proc Natl Acad Sci USA 101 2004 14631 14638
5. A. Zippelius, M.J. Pittet, P. Batard, N. Rufer, M. de Smedt, P. Guillaume, K. Ellefsen, D. Valmori, D. Liénard, and J. Plum Thymic selection generates a large T cell pool recognizing a self-peptide in humans J Exp Med 195 2002 485 494
6. D. Lienard, D. Rimoldi, M. Marchand, P.Y. Dietrich, N. van Baren, C. Geldhof, P. Batard, P. Guillaume, M. Ayyoub, and M.J. Pittet Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA Cancer Immun 4 2004 4
7. D.E. Speiser, D. Liénard, N. Rufer, V. Rubio-Godoy, D. Rimoldi, F. Lejeune, A. Krieg, J.-C. Cerottini, and P. Romero Rapid and strong human CD8+ T cell responses to vaccination with peptide, incomplete Freund's adjuvant, and CpP oligodeoxynucleotide 7909 J Clin Invest 115 2005 739 746
8. JW. Smith II, E.B. Walker, B.A. Fox, D. Haley, K.P. Wisner, T. Doran, B. Fisher, L. Justice, W. Wood, and J. Vetto Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses J Clin Oncol 21 2003 1562 1573
9. E.B. Walker, D. Haley, W. Miller, K. Floyd, K.P. Wisner, N. Sanjuan, H. Maecker, P. Romero, H.M. Hu, and W.G. Alvord gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells Clin Cancer Res 10 2004 668 680
10. V. Karanikas, C. Lurquin, D. Colau, N. van Baren, C. De Smet, B. Lethé, T. Connerotte, V. Corbière, M-A. Demoitié, and D. Liénard Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus J Immunol 171 2003 4898 4904
11. D. Godelaine, J. Carrasco, S. Lucas, V. Karanikas, B. Schuler-Thurner, P.G. Coulie, G. Schuler, T. Boon, and A. Van Pel Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide J Immunol 171 2003 4893 4897
12. Y. Zhang, N. Renkvist, Z. Sun, B. Schuler-Thurner, N. Glaichenhaus, G. Schuler, T. Boon, P. van der Bruggen, and D. Colau A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4 peptide-pulsed dendritic cells Eur J Immunol 35 2005 1066 1075
13. B. Thurner, I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, and P. von den Driesch Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma J Exp Med 190 1999 1669 1678
14. + progenitor-derived dendritic cell vaccine Cancer Res 61 2001 6451 6458
15. C. Germeau, W. Ma, F. Schiavetti, C. Lurquin, E. Henry, N. Vigneron, F. Brasseur, B. Lethé, E. De Plaen, and T. Velu High frequency of anti-tumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens J Exp Med 201 2005 241 248 All five melanoma patients tested here have circulating anti-tumor T cells at high frequencies before vaccination. They outnumber anti-vaccine T cells by 10-10 000-fold. In one patient displaying objective tumor regression after vaccination, their specificity was analyzed in detail. These anti-tumor CTLs recognized antigens encoded by only two genes: MAGE-C2 and gp100. New CTL clones appeared after vaccination.
16. C. Lurquin, B. Lethé, V. Corbière, I. Théate, N. van Baren, P.G. Coulie, and T. Boon Contrasting frequencies of anti-tumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen J Exp Med 201 2005 249 257 A precise genetic dissection, using clonotypic PCR, of the respective distributions of anti-vaccine and other anti-tumor T cells in the blood and inside regressing metastases of a vaccinated melanoma patient. Surprisingly, anti-vaccine T cells constitute only a minority of lymphocytes infiltrating regressing tumors.
17. L.H. Butterfield, A. Ribas, V.B. Dissette, S.N. Amarnani, H.T. Vu, D. Oseguera, H.J. Wang, R.M. Elashoff, W.H. McBride, and B. Mukherji Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma Clin Cancer Res 9 2003 998 1008
18. M.L. Disis, T.A. Gooley, K. Rinn, D. Davis, M. Piepkorn, M.A. Cheever, K.L. Knutson, and K. Schiffman Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines J Clin Oncol 20 2002 2624 2632
19. K.M. Lally, S. Mocellin, G.A. Ohnmacht, M.B. Nielsen, M. Bettinotti, M.C. Panelli, V. Monsurro, and F.M. Marincola Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading Int J Cancer 93 2001 841 847
20. S. Morel, F. Lévy, O. Burlet-Schiltz, F. Brasseur, M. Probst-Kepper, A.-L. Peitrequin, B. Monsarrat, R. Van Velthoven, J.-C. Cerottini, and T. Boon Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells Immunity 12 2000 107 117
21. N. Meidenbauer, A. Zippelius, M.J. Pittet, M. Laumer, S. Vogl, J. Heymann, M. Rehli, B. Seliger, S. Schwarz, and F.A. Le Gal High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma Cancer Res 64 2004 6319 6326
22. R. Ganss, B. Arnold, and G.J. Hammerling Mini-review: overcoming tumor-intrinsic resistance to immune effector function Eur J Immunol 34 2004 2635 2641
23. N. Garbi, B. Arnold, S. Gordon, G.J. Hammerling, and R. Ganss CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction J Immunol 172 2004 5861 5869 A convincing illustration that intratumoral microvessels are non-permissive for T cell infiltration. Interestingly, this can be reversed with systemic administration of CpG. It could explain some of the clinical effects observed in human cancers with this adjuvant
24. P.P. Lee, C. Yee, P.A. Savage, L. Fong, D. Brockstedt, J.S. Weber, D. Johnson, S. Swetter, J. Thompson, and P.D. Greenberg Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients Nat Med 5 1999 677 685
25. + T cells, the frequency of which enables tightly controlled functional assays, describes a state of quiescence of primed T lymphocytes present in lymph nodes invaded by melanoma cells, and in non lymphoid metastases from several patients. The functional defect, characterized by the absence of IFN-γ secretion after peptide stimulation, is reversible after culture with low dose IL-2 and IL-7.
26. D.H. Munn, E. Shafizadeh, J.T. Attwood, I. Bondarev, A. Pashine, and A.L. Mellor Inhibition of T cell proliferation by macrophage tryptophan catabolism J Exp Med 189 1999 1363 1372
27. C. Uyttenhove, L. Pilotte, I. Theate, V. Stroobant, D. Colau, N. Parmentier, T. Boon, and B.J. Van den Eynde Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nat Med 9 2003 1269 1274 The intra-tumoral nutrient shortage analyzed here could be an important cause of lymphocyte quiescence. The results suggest that inhibiting the responsible enzyme, IDO, could be a valuable addition to classical vaccinations.
28. D.H. Munn, M.D. Sharma, D. Hou, B. Baban, J.R. Lee, S.J. Antonia, J.L. Messina, P. Chandler, P.A. Koni, and A.L. Mellor Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes J Clin Invest 114 2004 280 290
29. P.C. Rodriguez, A.H. Zea, K.S. Culotta, J. Zabaleta, J.B. Ochoa, and A.C. Ochoa Regulation of T cell receptor CD3zeta chain expression by L-arginine J Biol Chem 277 2002 21123 21129
30. P.C. Rodriguez, A.H. Zea, J. DeSalvo, K.S. Culotta, J. Zabaleta, D.G. Quiceno, J.B. Ochoa, and A.C. Ochoa L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes J Immunol 171 2003 1232 1239
31. P.C. Rodriguez, D.G. Quiceno, J. Zabaleta, B. Ortiz, A.H. Zea, M.B. Piazuelo, A. Delgado, P. Correa, J. Brayer, and E.M. Sotomayor Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses Cancer Res 64 2004 5839 5849
32. W.W. Overwijk, M.R. Theoret, S.E. Finkelstein, D.R. Surman, L.A. de Jong, F.A. Vyth-Dreese, T.A. Dellemijn, P.A. Antony, P.J. Spiess, and D.C. Palmer Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells J Exp Med 198 2003 569 580
33. C. Yee, J.A. Thompson, D. Byrd, S.R. Riddell, P. Roche, E. Celis, and P.D. Greenberg Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells Proc Natl Acad Sci USA 99 2002 16168 16173
34. + lymphocytes.
35. M. Liu, B. Acres, J.M. Balloul, N. Bizouarne, S. Paul, P. Slos, and P. Squiban Gene-based vaccines and immunotherapeutics Proc Natl Acad Sci USA 101 2004 14567 14571
36. L. Gorelik, and R.A. Flavell Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells Nat Med 7 2001 1118 1122
37. G.A. Rabinovich, L.G. Baum, N. Tinari, R. Paganelli, C. Natoli, F.T. Liu, and S. Iacobelli Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 23 2002 313 320
38. N. Rubinstein, M. Alvarez, N.W. Zwirner, M.A. Toscano, J.M. Ilarregui, A. Bravo, J. Mordoh, L. Fainboim, O.L. Podhajcer, and G.A. Rabinovich Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege Cancer Cell 5 2004 241 251
39. + clones, and this effect is not abrogated by IL-2.
40. T.J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J.R. Conejo-Garcia, L. Zhang, and M. Burow Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 2004 942 949 The first description of what appears to be a non-antigen-specific recruitment of regulatory T cells in a human cancer, through CCL22 produced by ovarian cancer cells and stromal macrophages.
41. M. Viguier, F. Lemaitre, O. Verola, M.S. Cho, G. Gorochov, L. Dubertret, H. Bachelez, P. Kourilsky, and L. Ferradini Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells J Immunol 173 2004 1444 1453
42. M. de la Rosa, S. Rutz, H. Dorninger, and A. Scheffold Interleukin-2 is essential for CD4+CD25+ regulatory T cell function Eur J Immunol 34 2004 2480 2488
43. F. Fallarino, U. Grohmann, K.W. Hwang, C. Orabona, C. Vacca, R. Bianchi, M.L. Belladonna, M.C. Fioretti, M.L. Alegre, and P. Puccetti Modulation of tryptophan catabolism by regulatory T cells Nat Immunol 4 2003 1206 1212 A description of a mechanism of inhibition by unstimulated Tregs. Through CTLA-4, they interact with B7 on DCs and induce the expression of IDO. This could be an important regulatory mechanism in tumors in which Tregs accumulate, after being attracted by chemokines.
44. S.A. Rosenberg, J.C. Yang, and N.P. Restifo Cancer immunotherapy: moving beyond current vaccines Nat Med 10 2004 909 915
45. N.C. Twine, J.A. Stover, B. Marshall, G. Dukart, M. Hidalgo, W. Stadler, T. Logan, J. Dutcher, G. Hudes, and A.J. Dorner Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma Cancer Res 63 2003 6069 6075
46. T. Xu, C.T. Shu, E. Purdom, D. Dang, D. Ilsley, Y. Guo, J. Weber, S.P. Holmes, and P.P. Lee Microarray analysis reveals differences in gene expression of circulating CD8(+) T cells in melanoma patients and healthy donors Cancer Res 64 2004 3661 3667
47. + effector T cells, and is always preceded by inhibition of intra-tumoral angiogenesis.
48. T. Schuler, and T. Blankenstein Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells J Immunol 170 2003 4427 4431